Shirani-Bidabadi, ShivaTabatabaee, AliyeTavazohi, NazitaHariri, AmiraliAref, Amir RezaZarrabi, AliCasarcia, Nicolette2024-05-192024-05-1920230171-93351618-1298https://doi.org10.1016/j.ejcb.2023.151299https://hdl.handle.net/20.500.12713/4851Background: Drug resistance is a serious challenge in cancer treatment that can render chemotherapy a failure. Understanding the mechanisms behind drug resistance and developing novel therapeutic approaches are cardinal steps in overcoming this issue. Clustered regularly interspaced short palindrome repeats (CRISPR) gene-editing technology has proven to be a useful tool to study cancer drug resistance mechanisms and target the responsible genes. In this review, we evaluated original research studies that used the CRISPR tool in three areas related to drug resistance, namely screening resistance-related genes, generating modified models of resistant cells and animals, and removing resistance by genetic manipulation. We reported the targeted genes, study models, and drug groups in these studies. In addition to discussing different applications of CRISPR technology in cancer drug resistance, we analyzed drug resistance mechanisms and provided examples of CRISPR's role in studying them. Although CRISPR is a powerful tool for examining drug resistance and sensitizing resistant cells to chemo-therapy, more studies are required to overcome its disadvantages, such as off-target effects, immunotoxicity, and inefficient delivery of CRISPR/cas9 into the cells.eninfo:eu-repo/semantics/openAccessCancerDrug ResistanceCrispr TechnologyCancer TherapyArticle102236809688WOS:0009486591000012-s2.0-85148338225N/A10.1016/j.ejcb.2023.151299Q1